EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modified Guizhi Plus Huangqi Decoction Improves Antiphospholipase A2 Receptor Antibody–Induced Podocyte Injury Through Modulating Autophagy‐Related Markers via AMPK/mTOR Pathway

Manxia Huang, Yangpu Li, Zhishu Yang, Yunxin Lin, Zhuoting Liu, Zilan Jiang, Tingting Tan, Xinhui Liu, Youjia Zeng

Journal of Clinical Pharmacy and Therapeutics · 2026-01 · 2026 (1)

DOI: 10.1155/jcpt/8039321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 23.02.2026. Verfasst von Manxia Huang und 8 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Provincial Bureau of Quality and Technical Supervision, Shenzhen Science and Technology Innovation Program, Sanming Project of Medicine in Shenzen Municipality.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phospholipase A2 receptor (PLA2R)–associated membranous nephropathy (MN) is a primary cause of nephrotic syndrome in adults. Modified Guizhi plus Huangqi decoction (MGPHD) has been clinically effective for PLA2R MN. This basic study was designed to investigate the efficacy and mechanisms of MGPHD in treating PLA2R MN.

Methods

A PLA2R MN mouse model was established by intraperitoneal injection of anti‐PLA2R antibodies in transgenic mice expressing PLA2R1 in podocytes. Mice were administered MGPHD for 10 consecutive days. 24‐h urine volume, urinary albumin/creatinine, biochemical parameters, and renal pathological changes were assessed. Western blotting evaluated proteins related to PLA2R, podocyte cytoskeleton, autophagy, and AMPK/mTOR pathway in renal tissues. Astragaloside IV and icariin in MGPHD were detected by liquid chromatography–tandem mass spectrometry (LC‐MS/MS). In vitro, anti‐PLA2R antibodies were used to establish a podocyte injury model in podocytes (AB 8/13). Molecular docking assessed the binding of the two compounds to podocyte cytoskeleton proteins. Western blot detection of related proteins in vitro was consistent with the results obtained in vivo.

Results

MGPHD treatment improved podocyte injury, increased 24‐h urine volume and serum albumin, and decreased urinary albumin/creatinine and serum cholesterol ( p < 0.05). Immunofluorescence showed a reduced deposition of PLA2R antigen and complement C3, and electron microscopy demonstrated a restored foot process morphology. Western blotting revealed downregulated PLA2R, P62, and p ‐mTOR/mTOR and upregulated α ‐actinin‐4, LC3II/I, and p ‐AMPK/AMPK ( p < 0.05). Anti‐PLA2R antibodies caused podocyte cytoskeleton rearrangement and autophagy‐related marker impairment in vitro, roughly consistent with in vivo Western blotting results. Molecular docking showed a stable binding of astragaloside IV and icariin to podocyte cytoskeleton proteins. Astragaloside IV and icariin at different doses protected podocytes by stabilizing AMPK/mTOR pathway autophagy‐related markers and reducing anti‐PLA2R antibody–induced injury.

Conclusions

MGPHD and its active components, astragaloside IV and icariin, effectively ameliorate anti‐PLA2R antibody–induced podocyte injury by partially restoring the podocyte cytoskeleton and modulating autophagy‐related markers, possibly through the AMPK/mTOR pathway.

Förderung

  • Guangdong Provincial Bureau of Quality and Technical Supervision
  • Shenzhen Science and Technology Innovation Program
  • Sanming Project of Medicine in Shenzen Municipality

Zitieren

APA

Huang, M., Li, Y., Yang, Z., Lin, Y., Liu, Z., Jiang, Z., Tan, T., Liu, X., & Zeng, Y. (2026). Modified Guizhi Plus Huangqi Decoction Improves Antiphospholipase A2 Receptor Antibody–Induced Podocyte Injury Through Modulating Autophagy‐Related Markers via AMPK/mTOR Pathway. Journal of Clinical Pharmacy and Therapeutics, 2026(1). https://doi.org/10.1155/jcpt/8039321

Vancouver

Huang M, Li Y, Yang Z, Lin Y, Liu Z, Jiang Z, et al. Modified Guizhi Plus Huangqi Decoction Improves Antiphospholipase A2 Receptor Antibody–Induced Podocyte Injury Through Modulating Autophagy‐Related Markers via AMPK/mTOR Pathway. Journal of Clinical Pharmacy and Therapeutics. 2026;2026(1). doi:10.1155/jcpt/8039321

BibTeX
@article{Huang2026,
  author = {Huang, Manxia and Li, Yangpu and Yang, Zhishu and Lin, Yunxin and Liu, Zhuoting and Jiang, Zilan and Tan, Tingting and Liu, Xinhui and Zeng, Youjia},
  title = {Modified Guizhi Plus Huangqi Decoction Improves Antiphospholipase A2 Receptor Antibody–Induced Podocyte Injury Through Modulating Autophagy‐Related Markers via AMPK/mTOR Pathway},
  journal = {Journal of Clinical Pharmacy and Therapeutics},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jcpt/8039321}
}
Kostenlos starten →